Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.
ODAC overwhelming majority voted that TRUQAP plus abiraterone and ADT demonstrated a favorable benefit risk profile for patients based on the CAPItello-281 Phase III trial results ...
Option exercise triggers $25M payment to Pinetree.
Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition
Barchart Research What to Expect from AZN Earnings AZN Generated April 28, 2026 Current Price $186.68 EPS Estimate $$2.57 Consensus Rating Moderate Buy Average Move 2.64% AstraZeneca's Oncology Portfolio...
Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled...
First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients
Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD
Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer
IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver...